A Phase II, Open-label, Randomized Study to Evaluate the Safety and Efficacy of PROCHYMAL IBD (ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion for the Treatment of Subjects Experiencing Moderate-to-severe Crohn's Disease That is Refractory to Steroids and Immune Suppressants

Trial Profile

A Phase II, Open-label, Randomized Study to Evaluate the Safety and Efficacy of PROCHYMAL IBD (ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion for the Treatment of Subjects Experiencing Moderate-to-severe Crohn's Disease That is Refractory to Steroids and Immune Suppressants

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Dec 2014

At a glance

  • Drugs Remestemcel-L (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Sponsors Osiris Therapeutics
  • Most Recent Events

    • 19 May 2014 New trial record
    • 21 Sep 2008
    • 03 Jul 2006
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top